ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2026
A Pharmacokinetic and Efficacy Study of FDA-Indexed Pharmaceutical-Grade Extended-Release Buprenorphine and Compounded Sustained-Release Buprenorphine in African Green Monkeys (Chlorocebus aethiops).
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compounded sustained-release buprenorphine (SRB) has historically been used at our institution for postoperative analgesia in African green monkeys (AGMs), but it is not FDA approved and lacks species-specific data. With the recent FDA indexing of pharmaceutical-grade extended-release buprenorphine (EXR; Ethiqa XR; Fidelis), we aimed to compare the pharmacokinetic (PK) profile using serial plasma sampling up to 96 hours and postoperative analgesic efficacy of EXR compared with SRB. A total of 10 AGMs (n = 5 per test article) received 0.2 mg/kg SC of either EXR or SRB to complete the PK study. For the efficacy study, 20 animals (n = 10 per test article) were monitored for 3 days postoperatively after EEG telemetry surgery with femoral artery catheterization for behavioral indicators of pain and adverse effects. Plasma buprenorphine levels were analyzed using liquid chromatography-tandem mass spectrometry. PK study observations included appetite, fecal output, and injection site reactions. Both formulations achieved plasma concentrations above the presumed therapeutic threshold (0.1 ng/mL) for up to 96 hours. SRB produced higher mean plasma levels at early time points (30 minutes, 4 hours), but the overall PK profiles were similar. Injection site reactions were minimal and resolved spontaneously. For the efficacy assessment, clinical observations were evaluated using a postoperative score sheet. No significant differences were observed in postoperative pain scores between groups. Both EXR and SRB at 0.2 mg/kg SC provided sustained therapeutic plasma levels up to 96 hours and were well tolerated in AGMs, with comparable efficacy in postoperative pain control. EXR offers a compliant and effective alternative to compounded SRB for analgesia in AGMs, supporting its use in laboratory settings and regulatory compliance with current guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.